Opdivo 40 Mg/4 ml İv İnfüzyonluk Çözelti Konsantresi İçeren Flakon

? \000. \0008 \000/ \000/ \000$ \0001 \0000 \000$ \000 \0007 \000$ \000/ \000? \0000 \000$ \0007 \000,

Opdıvo

40 mg/4 mL inf?zyonluk ??zelti konsantresi i?eren flakon \000' \000D \000P \000D \000U \000 \000\\ \000R \000O \000X \000\\ \000O \000D \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000? \000U \000 \000 Steril

\000x \000 \000 \000\( \000W \000N \000L \000Q \000 \000P \000D \000G \000G \000H \000 \000Q \000L \000Y \000R \000O \000X \000P \000D \000E \000G \000? \000U \000 \000 \000+ \000H \000U \000 \000 \000 \000P \000/ \000 \000L \000Q \000I \000? \000] \000\\ \000R \000Q \000O \000X \000N \000 \000o \000| \000] \000H \000O \000W \000L \000 \000N \000R \000Q \000V \000D \000Q \000W \000U \000H \000V \000L \000 \000 \000 \000 Etkin maddemg nivolumab i?erir. Her flakon 40 mg \(4 mL?de\ nivolumab i?erir. \0001 \000L \000Y \000R \000O \000X \000P \000D \000E \000 \000 \000U \000H \000N \000R \000P \000E \000L \000Q \000D \000Q \000W \000 \000' \0001 \000$ \000 \000W \000H \000N \000Q \000R \000O \000R \000M \000L \000V \000L \000 \000L \000O \000H \000 \000d \000L \000Q \000 \000K \000D \000P \000V \000W \000H \000U \000L \000 \000R \000Y \000H \000U \000 \000 \000\\ \000X \000P \000X \000U \000W \000D \000O \000? \000N \000\f \000 \000 \000Y \000? \000F \000X \000G \000X \000Q \000 \000H \000Q \000I \000H \000N \000V \000L \000\\ \000R \000Q \000O \000D \000U \000D \000 \000Y \000H \000 \000N \000D \000Q \000V \000H \000U \000H \000 \000N \000D \000U \000? \000? \000 \000V \000D \000Y \000X \000Q \000P \000D \000V \000? \000Q \000D \000 \000\\ \000D \000U \000G \000? \000P \000F \000? \000 \000 \000Q \000R \000U \000P \000D \000O \000G \000H \000 \000E \000D \000? \000? \000? \000? \000N \000O \000? \000N \000 \000V \000L \000V \000W \000H \000P \000L \000 \000W \000D \000U \000D \000I \000? \000Q \000G \000D \000Q \000 \000? \000U \000H \000W \000L \000O \000H \000Q \000 \000E \000L \000U \000 \000W \000? \000U \000 \000S \000U \000R \000W \000H \000L \000Q \000\f \000 \000 \000, \000J \000* \000 \000\f \000 \000 h?crelerinde ?retilen tamamen insana ?zg? bir anti-PD-1 monoklonal antikordur

\000x \000< \000D \000U \000G \000? \000P \000F \000? \000 \000P \000D \000G \000G \000H \000O \000H \000U : Sodyum sitrat dihidrat, sodyum klor?r \(bkz. B?l?m 2\, mannitol \(E421\, pentetik asit, polisorbat 80, sodyum hidroksit, hidroklorik asit ve enjeksiyonluk sudur.

z \000 \000% \000X \000 \000L \000O \000D \000o \000 \000H \000N \000 \000L \000] \000O \000H \000P \000H \000\\ \000H \000 \000W \000D \000E \000L \000G \000L \000U \000 \000 \000% \000X \000 \000? \000o \000J \000H \000Q \000 \000\\ \000H \000Q \000L \000 \000J \000? \000Y \000H \000Q \000O \000L \000O \000L \000N \000 \000E \000L \000O \000J \000L \000V \000L \000Q \000L \000Q \000 \000K \000? \000] \000O \000? \000 \000R \000O \000D \000U \000D \000N \000 \000E \000H \000O \000L \000U \000O \000H \000Q \000P \000H \000V \000L \000Q \000L \000 \000V \000D \000? \000O \000D \000\\ \000D \000F \000D \000N \000W \000? \000U \000 \000 \0000 \000H \000\\ \000G \000D \000Q \000D \000 \000J \000H \000O \000H \000Q \000 \000K \000H \000U \000K \000D \000Q \000J \000L \000 \000E \000L \000U \000 \000\\ \000D \000Q \000 \000H \000W \000N \000L \000\\ \000L \000 \000U \000D \000S \000R \000U \000O \000D \000\\ \000D \000U \000D \000N \000 \000\\ \000D \000U \000G \000? \000P \000F \000? \000 \000R \000O \000D \000E \000L \000O \000L \000U \000V \000L \000Q \000L \000] \000 \000 \000< \000D \000Q \000 \000H \000W \000N \000L \000O \000H \000U \000L \000Q \000 \000Q \000D \000V \000? \000O \000 \000U \000D \000S \000R \000U \000O \000D \000Q \000D \000F \000D \000? \000? \000Q \000? \000 \000| \000? \000U \000H \000Q \000P \000H \000N \000 \000L \000o \000L \000Q \000 \000 \000 \000 \000% \000| \000O \000? \000P \000? \000Q \000 \000V \000R \000Q \000X \000Q \000D \000 \000E \000D \000N \000D \000E \000L \000O \000L \000U \000V \000L \000Q \000L \000] \000 \000

U \000% \000X \000 \000. \000X \000O \000O \000D \000Q \000P \000D \000 \0007 \000D \000O \000L \000P \000D \000W \000? \000Q \000G \000D U :

1. \0002 \0003 \000' \000, \0009 \0002 \000 \000Q \000H \000G \000L \000U \000 \000Y \000H \000 \000Q \000H \000 \000L \000o \000L \000Q \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000? \000U \000" 2. OPDIVO?yu kullanmadan ?nce dikkat edilmesi gerekenler 3. \0002 \0003 \000' \000, \0009 \0002 \000 \000Q \000D \000V \000? \000O \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000? \000U \000" 4. \0002 \000O \000D \000V \000? \000 \000\\ \000D \000Q \000 \000H \000W \000N \000L \000O \000H \000U \000 \000Q \000H \000O \000H \000U \000G \000L \000U \000" 5. \0002 \0003 \000' \000, \0009 \0002 \000? \000Q \000X \000Q \000 \000V \000D \000N \000O \000D \000Q \000P \000D \000V \000?

\000% \000D \000? \000O \000? \000N \000O \000D \000U \000? \000 \000\\ \000H \000U \000 \000D \000O \000P \000D \000N \000W \